ZIM
AEGR

Zacks Investment Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Zacks Investment Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-49,825
Closed -$74K – 780
2016
Q2 		$74K Buy
+49,825
New +$114K ﹤0.01% 612

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Zacks Investment Management's AEGR Position: Q3 2016 in Review

Zacks Investment Management sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2016, closing a stake of 49,825 shares — an estimated $74K sold.

Zacks Investment Management first reported a position in AEGR in Q2 2016 and held it in 1 quarter. The position peaked at $74K in Q2 2016. 58 funds tracked by Wall St. Rank hold AEGR as of Q3 2016.

  • Zacks Investment Management reported no remaining Aegerion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Zacks Investment Management sold 49,825 Aegerion Pharmaceuticals shares in Q3 2016, an estimated $74K.
  • Zacks Investment Management first reported a position in Aegerion Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Zacks Investment Management's Aegerion Pharmaceuticals position peaked at $74K in Q2 2016.
  • 58 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2016.

Based on Zacks Investment Management's 13F filing for Q3 2016, filed 14 Nov 2016.